Table 4.
Achievement of NEDA-3 and NEDA-4 during the 2-year follow-up in Group 1 and Group 2.
| NEDA-3 | NEDA-4 | Relapses | ||||
|---|---|---|---|---|---|---|
| Group | No(n) | Yes(n) | No(n) | Yes(n) | >0 (n) | 0 (n) |
| Group 1* | 8 | 11 | 12 | 7 | 6 | 13 |
| Group 2** | 14 | 2 | 15 | 1 | 5 | 13 |
| p-value | 0.012 | 0.047 | 1.000 | |||
*
Group 1 = Patients with no thalamic or whole BP atrophy.
**
Group 2 = Patients with thalamic atrophy and no whole BP atrophy.
Prevalence of NEDA3-No: 63%.
Sensitivity: 64%.
Specificity: 85%.
Positive predictive value: 88%.
Negative predictive value: 58%.
Odds ratio (OR) [95% CI]: 9.6 [1.69, 54.79].
The bold values indicate statistically significant p-values.